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CDC Recommendations: Good Laboratory Practices for 
Biochemical Genetic Testing and Newborn Screening for 
Inherited Metabolic Disorders
Shahram Shahangian and Bin Chen*
Division of Laboratory Science and Standards, Office of Surveillance, Epidemiology and 
Laboratory Services, Centers for Disease Control and Prevention, Atlanta, GA.
On April 6, 2012, the Centers for Disease Control and Prevention (CDC) published 
recommendations for good laboratory practices that address the quality-management needs 
of biochemical genetic testing and newborn screening (1). The CDC recommendations were 
developed on the basis of the recommendations and input of 3 federal advisory committees 
(the Clinical Laboratory Improvement Advisory Committee; the Secretary’s Advisory 
Committee on Genetics, Health, and Society; and the Secretary’s Advisory Committee on 
Heritable Disorders in Newborns and Children), as well as stakeholders and organizations 
representing newborn-screening laboratories. The specific areas covered in these 
recommendations include quality-management systems; planning and preparing for the 
introduction of new tests; establishing and verifying test performance; preanalytical (e.g., 
provision of test information, informed consent, test requests, specimen submission), 
analytical (e.g., quality control, proficiency testing, and alternative performance assessment), 
and postanalytical (e.g., test result reporting, result record retention, quality assessment) 
aspects; confidentiality of patient information and test results; and personnel qualifications 
and responsibilities. These recommendations provide a comprehensive guide for all those 
involved in laboratory testing for the screening, detection, diagnosis, monitoring, and 
clinical management of inherited metabolic diseases.
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